AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31262846 — intervention group
Group type: COMPARATOR
Intervention: Face-to-Face Consultations (FTFC)
Number of subjects: 149
Study 31262846 — intervention group
Group type: COMPARATOR
Intervention: Telephone Consultations (TC)
Number of subjects: 149
Study 27749966 — intervention group
Group type: EXPERIMENTAL
Intervention: Manualised program for early-onset conduct problems
Number of subjects: 58
Study 27749966 — intervention group
Group type: COMPARATOR
Intervention: Control group (30 families)
Number of subjects: 58
Study 26082085 — intervention group
Group type: EXPERIMENTAL
Intervention: Alginate-hydrogel in combination with standard medical therapy
Number of subjects: 78
Study 26082085 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy alone (Control)
Number of subjects: 78
Study 23883807 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate (FF) nasal spray at 110 μg once daily for 12 weeks
Number of subjects: 33
Study 23883807 — intervention group
Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 33
Study 21506020 — intervention group
Group type: EXPERIMENTAL
Intervention: Credit and family planning services provided together
Number of subjects: 0
Study 21506020 — intervention group
Group type: EXPERIMENTAL
Intervention: Only credit services provided
Number of subjects: 0
Study 21506020 — intervention group
Group type: EXPERIMENTAL
Intervention: Only family planning services provided
Number of subjects: 0
Study 21506020 — intervention group
Group type: COMPARATOR
Intervention: Control group (no services provided)
Number of subjects: 0
Study 19297788 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (bisphosphonate), once-weekly treatment for 6 months
Number of subjects: 60
Study 19297788 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment, once-weekly for 6 months
Number of subjects: 60
Study 17678456 — intervention group
Group type: EXPERIMENTAL
Intervention: Female patients
Number of subjects: 509
Study 17678456 — intervention group
Group type: COMPARATOR
Intervention: Male patients
Number of subjects: 509
Study 17194255 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA; 34 g dextrose)
Number of subjects: 51
Study 17194255 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine (b‐Ala; 1.6 g b‐Ala plus 34 g dextrose)
Number of subjects: 51
Study 17194255 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (CrM; 5.25 g CrM plus 34 g dextrose)
Number of subjects: 51
Study 17194255 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-alanine plus creatine (CrBA; 5.25 g CrM plus 1.6 g b‐Ala plus 34 g dextrose)
Number of subjects: 51
Study 12692611 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium phosphate mouth rinse (Caphosol) with fluoride treatments
Number of subjects: 95
Study 12692611 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of fluoride rinsing and placebo tray treatments
Number of subjects: 95
Study 10584132 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg/m2 amifostine i.v., 30 minutes before radiation
Number of subjects: 26
Study 10584132 — intervention group
Group type: COMPARATOR
Intervention: Control group (no amifostine)
Number of subjects: 26
Study 8914871 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow reserve after angioplasty
Number of subjects: 14
Study 8914871 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow reserve at predischarge
Number of subjects: 14
Study 8914871 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary flow reserve at follow-up
Number of subjects: 14
Study 8914871 — intervention group
Group type: COMPARATOR
Intervention: Coronary flow reserve in infarct patients vs reference patients
Number of subjects: 14
Study 8914871 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct region wall motion after angioplasty
Number of subjects: 14
Study 8914871 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct region wall motion at predischarge
Number of subjects: 14
Study 8914871 — intervention group
Group type: EXPERIMENTAL
Intervention: Infarct region wall motion at follow-up
Number of subjects: 14
Study 1877263 — intervention group
Group type: EXPERIMENTAL
Intervention: sucralfate 2 g q12h for five doses with ciprofloxacin 750 mg concurrently (Treatment A)
Number of subjects: 12
Study 1877263 — intervention group
Group type: EXPERIMENTAL
Intervention: ciprofloxacin 750 mg administered two hours before the fifth dose of sucralfate (Treatment B)
Number of subjects: 12
Study 1877263 — intervention group
Group type: EXPERIMENTAL
Intervention: ciprofloxacin 750 mg six hours before the fifth dose of sucralfate (Treatment C)
Number of subjects: 12
Study 1877263 — intervention group
Group type: COMPARATOR
Intervention: ciprofloxacin 750 mg alone (Treatment D)
Number of subjects: 12
Study 6311789 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (single dose preoperatively)
Number of subjects: 68
Study 6311789 — intervention group
Group type: COMPARATOR
Intervention: Cefotaxime (three doses perioperatively)
Number of subjects: 68
Study 29481976 — intervention group
Group type: EXPERIMENTAL
Intervention: Online ACT + TAU
Number of subjects: 67
Study 26320001 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Science doctrine‐based group psychotherapy (n = 58), 5 sessions of 90 minutes each at one-week intervals
Number of subjects: 118
Study 26320001 — intervention group
Group type: COMPARATOR
Intervention: Standard care including medication (n = 60)
Number of subjects: 118
Study 26571315 — intervention group
Group type: EXPERIMENTAL
Intervention: 20G biopsy needle
Number of subjects: 122
Study 26571315 — intervention group
Group type: COMPARATOR
Intervention: 18G biopsy needle
Number of subjects: 122
Study 24325104 — intervention group
Group type: EXPERIMENTAL
Intervention: HPC (hypoxia preconditioning)
Number of subjects: 40
Study 24325104 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 19874474 — intervention group
Group type: EXPERIMENTAL
Intervention: VKORC1 and CYP2C9 genotypes
Number of subjects: 223
Study 19874474 — intervention group
Group type: EXPERIMENTAL
Intervention: INR and prior doses
Number of subjects: 223
Study 18282607 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified version of the 'Mother‐Infant Transaction Program' (intervention group of preterm infants)
Number of subjects: 145
Study 18282607 — intervention group
Group type: COMPARATOR
Intervention: Control group of preterm infants
Number of subjects: 145
Study 18282607 — intervention group
Group type: COMPARATOR
Intervention: Healthy term infants (control group)
Number of subjects: 145
Study 15984968 — intervention group
Group type: EXPERIMENTAL
Intervention: omeprazole 20 mg od
Number of subjects: 512
Study 15984968 — intervention group
Group type: EXPERIMENTAL
Intervention: ranitidine 150 mg bid
Number of subjects: 512
Study 15984968 — intervention group
Group type: EXPERIMENTAL
Intervention: cisapride 20 mg bid
Number of subjects: 512
Study 15984968 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 512
Study 12024137 — intervention group
Group type: EXPERIMENTAL
Intervention: Pediatric colonoscope (PCF‐100, Olympus)
Number of subjects: 100
Study 12024137 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscope (CF‐100L or CF‐Q140L, Olympus)
Number of subjects: 100
Study 12024137 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 100
Study 10484598 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intensity cycling (6.3 +/- 1.7%)
Number of subjects: 18
Study 10484598 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher intensity cycling (13.3 +/- 3.8%)
Number of subjects: 18
Study 10484598 — intervention group
Group type: EXPERIMENTAL
Intervention: Static handgrip at 2-3 min (3.8 +/- 1.1%)
Number of subjects: 18
Study 10484598 — intervention group
Group type: EXPERIMENTAL
Intervention: Static handgrip at 4-5 min (8.6 +/- 2.8%)
Number of subjects: 18
Study 10484598 — intervention group
Group type: EXPERIMENTAL
Intervention: Postexercise cuff occlusion (-5.5 +/- 1.2%)
Number of subjects: 18
Study 8732108 — intervention group
Group type: EXPERIMENTAL
Intervention: ACNU, 5-Fu and ADM (Group B)
Number of subjects: 103
Study 8732108 — intervention group
Group type: COMPARATOR
Intervention: Me-CCNU, 5-Fu and ADM (Group A)
Number of subjects: 103
Study 1672481 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiprolol (200, 400, 600 mg once daily)
Number of subjects: 140
Study 1672481 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (total daily dose 80, 160, 320 mg twice daily)
Number of subjects: 140
Study 7151849 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 cm visual analogue scale
Number of subjects: 12
Study 7151849 — intervention group
Group type: EXPERIMENTAL
Intervention: 0‐10 point numerical rating scale
Number of subjects: 12
Study 7151849 — intervention group
Group type: COMPARATOR
Intervention: four‐point verbal descriptive scale
Number of subjects: 12
Study 31629570 — intervention group
Group type: EXPERIMENTAL
Intervention: dPly/PhtD vaccine (10 µg dPly and 10 µg PhtD) co-administered with 13-valent PCV (PCV13)
Number of subjects: 1803
Study 31629570 — intervention group
Group type: COMPARATOR
Intervention: Placebo co-administered with 13-valent PCV (PCV13)
Number of subjects: 1803
Study 27562778 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B12
Number of subjects: 171
Study 27562778 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study 25940212 — intervention group
Group type: EXPERIMENTAL
Intervention: Nucleus accumbens stimulation
Number of subjects: 4
Study 23432056 — intervention group
Group type: EXPERIMENTAL
Intervention: Unattended speech with high intensity motivation words
Number of subjects: 0
Study 23432056 — intervention group
Group type: EXPERIMENTAL
Intervention: Unattended speech with low intensity motivation words
Number of subjects: 0
Study 23432056 — intervention group
Group type: EXPERIMENTAL
Intervention: Conversation depicting intrinsic motivation
Number of subjects: 0
Study 23432056 — intervention group
Group type: COMPARATOR
Intervention: Unintelligible conversation
Number of subjects: 0
Study 21869692 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg rimonabant
Number of subjects: 10
Study 21869692 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg rimonabant
Number of subjects: 10
Study 21869692 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 19687793 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate (LF) diet (20-25% of energy from fat, 60-65% from CHO)
Number of subjects: 771
Study 19687793 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat, low-carbohydrate (HF) diet (40-45% of energy from fat, 40-45% from CHO)
Number of subjects: 771
Study 19687793 — intervention group
Group type: COMPARATOR
Intervention: Low-fat, high-carbohydrate (LF) diet
Number of subjects: 771
Study 17894256 — intervention group
Group type: EXPERIMENTAL
Intervention: Full subsidization
Number of subjects: 132
Study 17894256 — intervention group
Group type: COMPARATOR
Intervention: Partial subsidization
Number of subjects: 132
Study 17894256 — intervention group
Group type: EXPERIMENTAL
Intervention: Researcher monitoring
Number of subjects: 132
Study 17894256 — intervention group
Group type: COMPARATOR
Intervention: Self monitoring
Number of subjects: 132
Study 12621596 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentagastrin (0.2 micro g/kg)
Number of subjects: 24
Study 12621596 — intervention group
Group type: EXPERIMENTAL
Intervention: TRH (600 or 1200 micro g)
Number of subjects: 24
Study 12621596 — intervention group
Group type: COMPARATOR
Intervention: Flumazenil (2 mg)
Number of subjects: 24
Study 12621596 — intervention group
Group type: COMPARATOR
Intervention: Pentagastrin (0.1 micro g/kg)
Number of subjects: 24
Study 11188493 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.56 g/kg of alcohol
Number of subjects: 28
Study 11188493 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 9189784 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation
Number of subjects: 12
Study 9189784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1415022 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha (IFN alpha) therapy
Number of subjects: 127
Study 3893681 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-16-213 (Group 1: n = 25)
Number of subjects: 81
Study 3893681 — intervention group
Group type: COMPARATOR
Intervention: VP-16-213 + Cyclophosphamide (Group 2: n = 24)
Number of subjects: 81
Study 3893681 — intervention group
Group type: EXPERIMENTAL
Intervention: VP-16-213 + Doxorubicin (Group 3: n = 32)
Number of subjects: 81
Study 31130429 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting for symptomatic vertebral artery stenosis
Number of subjects: 354
Study 31130429 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment for symptomatic vertebral artery stenosis
Number of subjects: 354
Study 31130429 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting for extracranial stenosis
Number of subjects: 354
Study 31130429 — intervention group
Group type: EXPERIMENTAL
Intervention: Stenting for intracranial stenosis
Number of subjects: 354
Study 28264082 — intervention group
Group type: EXPERIMENTAL
Intervention: Advice to increase water intake to 8 cups per day
Number of subjects: 38
Study 28264082 — intervention group
Group type: COMPARATOR
Intervention: Control group (no advice to increase water intake)
Number of subjects: 38
Study 25686399 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral tegafur-uracil (UFT) at 600 mg/day
Number of subjects: 309
Study 25686399 — intervention group
Group type: COMPARATOR
Intervention: Control group (no UFT treatment)
Number of subjects: 309
Study 25686399 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral tegafur-uracil (UFT)
Number of subjects: 309
Study 22717130 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative information pertaining to an anomalous experience (a card trick)
Number of subjects: 0
Study 22717130 — intervention group
Group type: COMPARATOR
Intervention: Neutral information pertaining to an anomalous experience (a card trick)
Number of subjects: 0
Study 21852010 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy plus radiation
Number of subjects: 681
Study 21852010 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy alone
Number of subjects: 681
Study 19951850 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and exercise habits (not specified in detail)
Number of subjects: 6600
Study 17062772 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 12
Study 15266763 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotrimazole 200 mg vaginal tablets
Number of subjects: 223
Study 11533342 — intervention group
Group type: EXPERIMENTAL
Intervention: Home nurse visit
Number of subjects: 1014
Study 11533342 — intervention group
Group type: COMPARATOR
Intervention: Hospital-based follow-up (control)
Number of subjects: 1014
Study 9875578 — intervention group
Group type: EXPERIMENTAL
Intervention: Live recombinant canarypox-HIV-1 vaccine (given at days 0, 7, 14, and 21)
Number of subjects: 0
Study 9875578 — intervention group
Group type: EXPERIMENTAL
Intervention: Subunit gp120 vaccine (given at days 28 and 84)
Number of subjects: 0
Study 9875578 — intervention group
Group type: COMPARATOR
Intervention: Unprimed controls (received two doses of subunit vaccine)
Number of subjects: 0
Study 7612066 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc sulfate gel (Virudermin Gel)
Number of subjects: 0
Study 7612066 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 0
Study 2116311 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine 5-10 mg b.i.d.
Number of subjects: 20
Study 2116311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 353831 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepiprazole
Number of subjects: 0
Study 31959585 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical cannabis (MC) users
Number of subjects: 128
Study 31959585 — intervention group
Group type: COMPARATOR
Intervention: Non-MC users
Number of subjects: 128
Study 31959585 — intervention group
Group type: EXPERIMENTAL
Intervention: Frequent MC use
Number of subjects: 128
Study 30239213 — intervention group
Group type: EXPERIMENTAL
Intervention: Xbox 360 Kinect cognitive games
Number of subjects: 44
Study 30239213 — intervention group
Group type: COMPARATOR
Intervention: Control group (range of motion exercises only)
Number of subjects: 44
Study 27611958 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile app treatment (Tät®) focused on pelvic floor muscle training (PFMT)
Number of subjects: 123
Study 27611958 — intervention group
Group type: COMPARATOR
Intervention: Control group (postponed treatment)
Number of subjects: 123
Study 26051508 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized Feedback Interventions (PFIs)
Number of subjects: 50
Study 26051508 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 50
Study 23481667 — intervention group
Group type: EXPERIMENTAL
Intervention: Shang Ring device
Number of subjects: 0
Study 23481667 — intervention group
Group type: COMPARATOR
Intervention: Dorsal slit technique
Number of subjects: 0
Study 21649839 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose amlodipine/olmesartan medoxomil (AML/OM) 5/20 mg, uptitrated to AML/OM 5/40 mg and 10/40 mg
Number of subjects: 999
Study 21649839 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose amlodipine/olmesartan medoxomil + hydrochlorothiazide (HCTZ) 10/40+25 mg
Number of subjects: 999
Study 21649839 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambulatory BP monitoring substudy (n=243)
Number of subjects: 999
Study 21649839 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-emergent adverse events (TEAEs)
Number of subjects: 999
Study 19656039 — intervention group
Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg daily
Number of subjects: 18000
Study 19656039 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18000
Study 16918857 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate intervention group
Number of subjects: 736
Study 16918857 — intervention group
Group type: COMPARATOR
Intervention: Delayed intervention group
Number of subjects: 736
Study 12673155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginseng (400 mg.d‐1 of G115; equivalent to 2 g of Panax ginseng C.A. Meyer root material)
Number of subjects: 38
Study 12673155 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 38
Study 10201761 — intervention group
Group type: EXPERIMENTAL
Intervention: Granisetron 40 microg/kg
Number of subjects: 120
Study 10201761 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 20 microg/kg
Number of subjects: 120
Study 10201761 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 0.2 mg/kg
Number of subjects: 120
Study 9552520 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent implantation
Number of subjects: 0
Study 9552520 — intervention group
Group type: COMPARATOR
Intervention: PTCA
Number of subjects: 0
Study 9552520 — intervention group
Group type: COMPARATOR
Intervention: BENESTENT‐I study
Number of subjects: 0
Study 9552520 — intervention group
Group type: COMPARATOR
Intervention: BENESTENT‐II pilot study
Number of subjects: 0
Study 9552520 — intervention group
Group type: COMPARATOR
Intervention: Phase IV of the BENESTENT‐II pilot study
Number of subjects: 0
Study 1988829 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vidarabine (30 mg/kg/day for 10 days)
Number of subjects: 202
Study 1988829 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir (30 mg/kg/day for 10 days)
Number of subjects: 202
Study 1988829 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine in babies with disease confined to the skin, eyes, or mouth
Number of subjects: 202
Study 1988829 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir in babies with disease confined to the skin, eyes, or mouth
Number of subjects: 202
Study 1988829 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine in babies with encephalitis
Number of subjects: 202
Study 1988829 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir in babies with encephalitis
Number of subjects: 202
Study 1988829 — intervention group
Group type: EXPERIMENTAL
Intervention: Vidarabine in babies with disseminated disease
Number of subjects: 202
Study 1988829 — intervention group
Group type: COMPARATOR
Intervention: Acyclovir in babies with disseminated disease
Number of subjects: 202
Study 6984223 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioplegic arrest and continuous cross‐clamping of aorta
Number of subjects: 40
Study 6984223 — intervention group
Group type: COMPARATOR
Intervention: Ischaemic arrest and intermittent cross‐clamping of aorta
Number of subjects: 40
Study 3987791 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg moclobemide
Number of subjects: 6
Study 3987791 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg moclobemide
Number of subjects: 6
Study 3987791 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg moclobemide
Number of subjects: 6
Study 3987791 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 31594772 — intervention group
Group type: EXPERIMENTAL
Intervention: South Gloucestershire pain and opioid review service
Number of subjects: 18
Study 31594772 — intervention group
Group type: EXPERIMENTAL
Intervention: GP recommendations for funding and clinical supervision
Number of subjects: 18
Study 29278869 — intervention group
Group type: EXPERIMENTAL
Intervention: Glenohumeral stabilization exercise (GSE)
Number of subjects: 40
Study 29278869 — intervention group
Group type: COMPARATOR
Intervention: Scapular stabilization exercise (SSE)
Number of subjects: 40
Study 27055414 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% cyclosporine A cationic emulsion (CsA CE) eye drops, once daily
Number of subjects: 246
Study 27055414 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 246
Study 27055414 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% cyclosporine A cationic emulsion (CsA CE) eye drops
Number of subjects: 246
Study 24616308 — intervention group
Group type: EXPERIMENTAL
Intervention: Docetaxel plus prednisone
Number of subjects: 0
Study 24616308 — intervention group
Group type: EXPERIMENTAL
Intervention: Rising CTC count from day 0 to 21
Number of subjects: 0
Study 24616308 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline CTC counts
Number of subjects: 0
Study 24616308 — intervention group
Group type: EXPERIMENTAL
Intervention: Adding day-0 CTCs to baseline PSA and other covariates
Number of subjects: 0